142 activities found

  • go
  • add

Chairmen's Corner: 15th European Congress: Perspectives in Lung Cancer - Post-ASCO Update

Chairmen Pieter E. Postmus and Giorgio V. Scagliotti provide highlights and key updates from the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, held from May 30-June 3, 2014, relative to the 15th European Congress: Perspectives in Lung Cancer held earlier this spring. This activity was made possible in part by Eli Lilly.
  • Audio
  • Video
  • Text
0 ACCME
  • go
  • add

Podium to Practice: Cornerstones Health and The UAMS College of Medicine Presents: Best of Digestive Diseases Week in Inflammatory Bowel Disease 2014

Cornerstones Health is pleased to present this Podium to Practiceâ„¢ Best of Digestive Diseases Week in Inflammatory Bowel Disease 2014 program. In these educational webisodes, a faculty of international experts share the most practical and important updates fresh from the podium which will immediately influence your care of patients with Inflammatory Bowel Disease (IBD) and provide a sustained impact on patient outcomes.
  • Audio
  • Video
  • Text
1 ACCME
  • go
  • add

Expert Perspectives: European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes

Filmed at the 2014 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes in Prague, this online activity is a video discussion between Dr. Srdan Verstovsek, MD, PhD and Dr. Alessandro M. Vannucchi, MD highlighting recent clinical advances in MPN/MDS presented during the conference. This engaging conversational format provides expert perspectives on current issues concerning diagnosis, prognosis and therapeutic regimens for the optimization of clinical outcomes and patient quality of life.
  • Audio
  • Video
  • Text
0.5 ACCME
  • go
  • add

Expert Perspectives: 2014 Great Debates & Updates in Hematology

Filmed at the 2014 Great Debates and Updates in Hematologic Malignancies Congress in New York, this online activity is comprised of three videos wherein Dr. James M. Epstein is joined by Drs. Robert Z. Orlowski, David P. Steensma, and John P. Leonard to discuss recent clinical advances in hematologic malignancies. This engaging conversational format provides expert perspectives on current clinical innovations in diagnosis, prognosis and therapeutic intervention in the areas of multiple myeloma, lymphoma, chronic lymphocytic leukemia, myeloproliferative neoplasms and myelodysplastic syndromes.
  • Audio
  • Video
  • Text
1 ACCME
  • go
  • add

Webcast: Double-Refractory Multiple Myeloma: A Case-Based Discussion of Novel Treatment Options

Patients with multiple myeloma that is refractory to both bortezomib and lenalidomide have an especially poor prognosis. This double-refractory indication is emerging as a significant clinical challenge as these two agents are now commonly used as frontline and maintenance therapies. However, recent research advances have led to the development of several novel agents for double-refractory myeloma, including the recently approved drugs carfilzomib and pomalidomide. This case-based symposium uses case studies and panel discussions to update hematologists, medical oncologists, and other health-care practitioners on the latest treatment strategies for bortezomib- and lenalidomide-refractory myeloma.
  • Audio
  • Video
  • Text
1 ACCME
  • go
  • add

Best of the Day: from the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

This series of interviews with eight expert faculty is filmed on location during the 2014 American Society of Clinical Oncology (ASCO) Annual meeting, where the most current cancer data is presented and examined. Following the scientific sessions, Dr. James Epstein reviews and explores some of the most significant research findings in multiple tumor types with internationally recognized investigators and practicing physicians. Abstracts for discussion were chosen according to clinical relevance.
  • Audio
  • Video
  • Text
4 ACCME
  • go
  • add

Interactive Case: Frontline Therapy for Transplant-Eligible Patient with Standard-Risk Multiple Myeloma

Dr. Fonseca discusses the optimal frontline management options for a transplant-eligible patient with standard-risk multiple myeloma (MM). He delineates the different induction therapy approaches and discusses the benefits and risks of standard and emerging regimens.
  • Audio
  • Video
  • Text
0.5 ACCME
  • go
  • add

Webcast: Advancements for Outcome Optimization in Myeloproliferative Neoplasms

Recent advances in basic and clinical research have enhanced our understanding of the underlying biological and genetic variations associated with myeloproliferative neoplasms. These advances have enhanced classification and diagnosis of disease, contributed to more robust risk stratification models and identified novel targeted therapies for the optimization of clinical outcomes and enhanced quality of life. However, clinical challenges involving diagnosis, assessment of prognosis and prediction of patient outcomes still remain. As we continue to develop our understanding of MPNs and the biological processes involved in myeloid proliferation, abnormal proliferation, and dysplasia, health care professionals must be kept current of these emerging, clinically relevant findings to provide optimal care to patients with MPNs enhancing quality of life and overall clinical outcomes.
  • Audio
  • Video
  • Text
1 ACCME
  • go
  • add

Interactive Case: Second-line Therapy for Diffuse Large B-Cell Lymphoma

Dr. Coleman discusses the contemporary treatment approaches for the management of an elderly patient with diffuse large B-cell lymphoma (DLBCL) of the ABC subtype. He elaborates on the clinical outcomes that have been noted with different management options including immunomodulatory agents, targeted therapy, and chemotherapeutic strategies in this patient subset and highlights their advantages and disadvantages.
  • Audio
  • Video
  • Text
0.5 ACCME
  • go
  • add

DocTalk: A Discussion about Screening, Risk Assessment, and Surveillance in Prostate Cancer

Several questions revolve around the best practices in screening, risk assessment, and management of early-stage prostate cancer. The inherent risks of over-diagnosis and over-treatment following PSA screening has triggered controversial discussions regarding the use of routine screening. Similarly, updated clinical guidelines are recommending the use of active surveillance for low-risk early prostate cancer based on data from recent studies. Furthermore, several new tools have been developed to more accurately assess prostate cancer risk and potential aggressiveness. The Doctalk: A Discussion about Screening, Risk Assessment, and Surveillance in Prostate Cancer is designed to inform community oncologists, urologists, and other health-care providers about recent controversies and evolving trends in prostate cancer screening and risk assessment, and their potential impact on routine clinical practice.
  • Audio
  • Video
  • Text
1.5 ACCME